The Effect of G6PD Enzyme and Some Clinical Parameters in Hypertensive Heart Disease Patients
Downloads
Background and Objective: "Due to its great incidence and the corresponding dangers of cardiovascular disease, hypertension is a major global public health concern. One of the most significant metabolite enzymes, glucose-6-phosphate dehydrogenase (G6PD) (also known as oxidoreductase; EC 1.1.1.1-49) is the primary enzyme and the key to the pentose phosphate pathway. It promotes the oxidation of glucose-6-phosphate (G-6-P) (NADP +) to preserve the pathways that many vital compounds use to produce life. People who have this oxidative damage status due to downregulated G6PD are more likely to develop cancer, diabetes, and cardiovascular diseases, among other degenerative ailments". Methodology: 200 "individuals between the ages of 30 and 69 who had hypertension and a control group were gathered. The following demographic information was noted: gender, age, height, weight, length of hypertension, length of treatment, and medical history, particularly fauvism. Measurements were also made of body mass index and blood pressure. One blood sample was taken from each patient and 5 elements including G6PD existence and activity, fasting plasma glucose, plasma Calcium, Magnesium and troponin".Results: G6PD "activity was substantially higher (P<0.05) in those in the control group. G6PD mean activity was substantially higher in the control group (P<0.05) and in participants with a BMI < 25 (P<0.05) when it came to hypertension. The control group's G6PD mean activity was substantially higher than that of the Ca,Mg hypertension control group (P<0.01). The relationship between troponin and hypertension was found to be positive (r=0.2681), with a higher concentration of troponin throughout the groups under study and a positive correlation with g6pd".Conclusion: "The biochemical marker G6PD activity can be used to diagnose hypertension, which can have major consequences and raise G6PD activity. This problem intensifies the damage caused by hypertension as a result of an improper antioxidation process. Obesity and dyslipidemia concurrently may exacerbate the effects of oxidative stress and hypertension.
Al-Rawi, K. M. 2024.Introduction to Statistics. five edition, College of Agriculture and Forestry, Mosul.
Black MH, Zhou H, Sacks DA, Dublin S, Lawrence JM, Harrison TN, et al. Prehypertension prior to or during early pregnancy is associated with increased risk for hypertensive disorders in pregnancy and gestational diabetes. J Hypertens. 2015;33:1860–1867.
Brewer AC, Mustafi SB, Murray TVA, Rajasekaran NS, Benjamin IJ. 2013. Reductive Stress Linked to Small HSPs, G6PD, and Nrf2 Pathways in Heart Disease. Antioxid Redox Signal 18:1114–1127.
Cappellini M, Fiorelli G. 2008. Glucose-6-phosphate dehydrogenase deficiency. Lancet (London, England) 371:64–74.
Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2018;371:64–74.
Cheng ML, Ho HY, Lin HY, Lai YC, Chiu DTY. 2013. Effective NET formation in neutrophils from individuals with G6PD Taiwan-Hakka is associated with enhanced NADP + biosynthesis. Free Radic Res 47:699–709.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. National Heart, lung, and blood institute joint national committee on prevention, detection, evaluation, and treatment of high blood pressurenational high blood pressure education program coordinating committee. the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2013;289:2560–72.
Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension. 2018;52:818–27.
Damoiseaux J., Andrade L.E.C., Carballo O.G., Conrad K., Frances cantonio P.L.C., Fritzler M.J., et al. Clinical relevance of HEp-2 indirect immune fluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann. Rheumat. Dis. 2019;78(7):878–888.
Denic, Vladimir. Molecular basis of fatty acid synthesis in the endoplasmic reticulum (ER) membrane and targeting of misfolded glycoproteins for ER-associated degradation. University of California, San Francisco, 2006.
DEY, Arindam. Etude des effets des nanoparticules sur le système immunitaire. 2020. PhD Thesis. Université Grenoble Alpes.
Ding D, Dan Z, Shao-ping Y, Meng-jie C, Duo-sheng J, Bi-fang P. Analysis on maternal death and intervention measures from 2015 to 2017 in Wuhan. Chin J Matern Child Health. 2020;25:4176–8.
Egner W. The use of laboratory tests in the diagnosis of SLE. Journal of clinical pathology. 2000;53(6):425–433.
Flack JM, Adekola B. Blood pressure and the new ACC/AHA hypertension guidelines. Trends Cardiovasc Med. 2020 Apr;30(3):160-164.
Fois A, Dore MP, Manca A, Scano V, Pirina P, Pes GM. 2021. Association between Glucose-6-Phosphate Dehydrogenase Deficiency and Asthma. J Clin Med 10:5639.
Frostegård, Johan, et al. "Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations." Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 52.1 (2005): 191-201.
Gheita TA, Kenawy SAB, El Sisi RW, Gheita HA, Khalil H. 2014. Subclinical reduced G6PD activity in rheumatoid arthritis and Sjögren’s Syndrome patients: relation to clinical characteristics, disease activity and metabolic syndrome. Mod Rheumatol 24:612–7.
Giovanni Mario Pes, Guido Parodi, Maria Pina Dore, Glucose-6-phosphate dehydrogenase deficiency and risk of cardiovascular disease: A propensity score-matched study, Atherosclerosis, Volume 282,2019, Pages 148-153.
Gupte, R., Dhagia, V., Ročić, P., & Ochi, R. Glucose-6-phosphate dehydrogenase increases ca2+currents by interacting with cav1.2 and reducing intrinsic inactivation of the l-type calcium channel. American Journal of Physiology-Heart and Circulatory Physiology (2020). 319(1), H144-H158.
Husain Q, Ahmad A, Shameem M. 2012. Relation of oxidant-antioxidant imbalance with disease progression in patients with asthma. Ann Thorac Med 7:226.
HYK, Lai NM, Lee SWH. 2022. Glucose-6-phosphate dehydrogenase deficiency and risk of diabetes: a systematic review and meta-analysis. Ann Hematol 96:839–845.
Israel A, Merzon E, Schäffer AA, Shenhar Y, Green I, Golan-Cohen A, Ruppin E, Magen E, Vinker S. 2021. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. BMJ 375:e067873.
Jump up to: a b c Dicker JW, van der Vlag J,Berden JH (Feb 2014). "Deranged removal of apoptotic cells: its role in the genesis of lupus". Nephrol. Dial. Transplant. 19 (2): 281–284.
Launay D., Schmidt J., Lepers S., Mirault T., Lambert M., Kyndt X., et al. Comparison of the Farr radioimmunoassay, 3 commercial enzyme immunoassays and Crithidia luciliae immunofluorescence test for diagnosis and activity assessment of systemic lupus erythematosus. Clin. Chim. Acta. 2010;411(13-14):959–965.
Liang Y, Liu R, Du S, Qiu C. Trends in incidence of hypertension in Chinese adults, 1991–2009: The China Health and Nutrition Survey. Int J Cardiol. 2018;175:196–01.
Mahmoud AA, Nor ElDin AK. Glucose-6-phosphate dehydrogenase activity and protein oxidative modification in patients with type 2 diabetes mellitus. J Biomark. 2023;20-23:4308.
Matsui R, Xu S, Maitland KA, Hayes A, Leopold JA, Handy DE, et al. Glucose-6 phosphate dehydrogenase deficiency decreases the vascular response to angiotensin II. Circulation. 2023; 112:257–63.
Mehmet Çiftçi, İsmail Özmen, M. Emin Büyükokuroğlu, Sadrettin Pençe, Ö. İrfan Küfrevioğlu, Effects of metamizol and magnesium sulfate on enzyme activity of glucose 6-phosphate dehydrogenase from human erythrocyte in vitro and rat erythrocyte in vivo, Clinical Biochemistry, Volume 34, Issue 4,2021, Pages 297-302.
Meloni L, Manca MR, Loddo I, Cioglia G, Cocco P, Schwartz A, Muntoni S, Muntoni S. Glucose-6-phosphate dehydrogenase deficiency protects against coronary heart disease. J Inherit Metab Dis .2008.31: 412–417.
MP, Davoli A, Longo N, Marras G, Pes GM. 2016. Glucose-6-phosphate dehydrogenase deficiency and risk of colorectal cancer in Northern Sardinia: A retrospective observational study. Medicine (Baltimore) 95:e5254.
MP, FanciulliG, Pes GM. 2023. IsGlucose-6-Phosphate Dehydrogenase Deficiency a Risk Factor for Autoimmune Thyroid Disease? A Retrospective Case–Control Study. Int J Environ Res Public Heal 2023, Vol 20, Page 2709 20:2709.
MP, Parodi G, Portoghese M, Pes GM. 2021. The Controversial Role of Glucose-6-Phosphate Dehydrogenase Deficiency on Cardiovascular Disease: A Narrative Review. Oxid Med Cell Longev 2021:5529256.
Niazi ZR, Silva GC, Ribeiro TP, Leon-Gonzalez AJ, Kassem M, Mirajkar A, et al. EPA: DHA 6:1 prevents angiotensin II-induced hypertension and endothelial dysfunction in rats: role of NADPH oxidase- and COX-derived oxidative stress. Hypertens Res. 2017; 40:966–75.
Nwankwo MU, Bunker CH, Ukoli FA, Omene JA, Freeman DT, Vergis EN, et al. Blood pressure and other cardiovascular disease risk factors in black adults with sickle cell trait or glucose-6-phosphate dehydrogenase deficiency. Genet Epidemiol. 2023; 7:211–8.
Smenk RJ (June 2010). "Antinuclear antibodies: cause of disease or caused by disease". Rheumatology (Oxford). 39 (6): 581-588.
Solak Y, Afsar B, Vaziri ND, Aslan G, Yalcin CE, Covic A, et al. Hypertension as an autoimmune and inflammatory disease. Hypertens Res. 2016; 39:567–73.
Touyz RM, Briones AM. Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens Res. 2021; 34:5–14.
Wang J, Zhang L, Wang F, Liu L, Wang Haiyan. Prevalence, awareness, treatment, and control of hypertension in China: results From a National Survey. Am J Hypertens. 2019;27:1355–61.
Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 .guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017;71:1269–324.
Wiesenfeld SL, Petrakis NL, Sams BJ, Collen MF, Cutler JL. Elevated blood pressure, pulse rate and serum creatinine in Negro males deficient in glucose-6-phosphate dehydrogenase. N Engl J Med. 2022; 282:1001–2.
World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guideline subcommittee, Journal of Hypertension, 2019.17(2),151–183.
Yi-qun W. Risk factor related to hypertensive disorders in pregnancy and effects of hypertension on pergnancy outcome. Chin J General Pract. 2015;13:602–4.
Zhang Z, Liew CW, Handy DE, Zhang Y, Leopold JA, Hu J, et al. High glucose inhibits glucose-6-phosphate dehydrogenase, leading to increased oxidative stress and beta-cell apoptosis. FASEB J. 2020; 24:1497–505.
